Treatment for New-onset Atrial Fibrillation (NOAF)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Maryland Medical Center, Baltimore, MD
New-onset Atrial Fibrillation (NOAF)+1 More
Eligibility
65+
Female
What conditions do you have?
Select

Study Summary

Screening for Atrial Fibrillation in Elderly Women (SAFE-W) is a pilot study evaluating the prevalence of atrial fibrillation (Afib) in a rapidly aging segment of the population. Studies have shown that women with Afib are more likely to be symptomatic, have increased mortality from stroke resulting from Afib, and are less likely to receive treatment for Afib. University of Maryland Department of Neurology and Vascular Neurology are recruiting women older than 70 years of age to participate in the study.

Eligible Conditions

  • New-onset Atrial Fibrillation (NOAF)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for New-onset Atrial Fibrillation (NOAF)

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: 2 years

1 year
Device adherence
Rate of detection of atrial fibrillation
2 years
Anticoagulant use for prevention of stroke

Trial Safety

Safety Progress

1 of 3

Other trials for New-onset Atrial Fibrillation (NOAF)

Trial Design

0 Treatment Group

120 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Trial Background

Prof. Prachi Mehndiratta, Assistant Professor
Principal Investigator
University of Maryland, Baltimore
Closest Location: University of Maryland Medical Center · Baltimore, MD
Photo of md university of maryland medical center  1Photo of md university of maryland medical center  2Photo of Baltimore  3
2016First Recorded Clinical Trial
1 TrialsResearching New-onset Atrial Fibrillation (NOAF)
185 CompletedClinical Trials

Eligibility Criteria

Age 65+ · Female Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.